Aptevo Therapeutics Stock (NASDAQ:APVO)


OwnershipFinancialsChart

Previous Close

$3.04

52W Range

$2.81 - $485.44

50D Avg

$5.36

200D Avg

$80.07

Market Cap

$2.14M

Avg Vol (3M)

$2.42M

Beta

5.73

Div Yield

-

APVO Company Profile


Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

37

IPO Date

Jul 20, 2016

Website

APVO Performance


APVO Financial Summary


Dec 24Dec 23Dec 22
Revenue--$3.11M
Operating Income$-24.60M$-28.88M$-28.64M
Net Income$-24.13M$-17.41M$42.67M
EBITDA$-24.60M$-28.31M$-27.74M
Basic EPS$-84.67$-2.32K$13.57K
Diluted EPS$-84.67$-2.32K$13.61K

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison


TickerCompany
SNOASonoma Pharmaceuticals, Inc.
SRZNSurrozen, Inc.
ADTXAditxt, Inc.
CAPRCapricor Therapeutics, Inc.
CRVSCorvus Pharmaceuticals, Inc.
KTTAPasithea Therapeutics Corp.